An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy. To explore the potential procarcinogenic role of this ERBB2 mutation, we conducted the present study using BC cells overexpressing wild...

Full description

Bibliographic Details
Main Authors: Zi-Yan Yang, Liu Yang, Chun-Wei Xu, Xiao-Jia Wang, Lei Lei
Format: Article
Language:English
Published: The Company of Biologists 2020-01-01
Series:Biology Open
Subjects:
breast cancer
erbb2
insertion mutation
lapatinib
akt
Online Access:http://bio.biologists.org/content/9/1/bio047662

Similar Items

Similar Items